Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Neurophth Starts China Trial of Gene Therapy for Hereditary Blindness

publication date: Jun 28, 2021

Neurophth Biotech, a Wuhan-San Diego gene therapy company, dosed the first patient in a China trial of a therapy for Leber hereditary optic neuropathy (LHON), which causes blindness in adult patients. The Phase I/II/III trial will evaluate the safety, tolerability and efficacy of a recombinant adeno-associated virus vector 2 carrying the NADH-dehydrogenase subunit 4 (ND4) gene. The disease currently has no cure. The safety and efficacy of ND4 gene therapy have been shown in three investigator-initiated trials with clinical durability of up to 90 months. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital